Elevation Oncology Inc ELEV
News
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2